Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mehta Analysis: Can Trump Trigger Triple Cascade?

Executive Summary

Trump says the biopharma industry can no longer depend on the higher US profit margins with his initiative to peg US drug prices to global norms. The US president needs second and third initiatives to be successful: Enable the regulators and biopharma industry to rationalize R&D, and to eliminate selling costs that collectively account for one-half of the industry, writes Viren Mehta, founding partner of Mehta Partners LLC.

You may also be interested in...



Mehta Analysis: The Promise Of 2021

Next year promises a wide range of opportunities for biopharma, triggered by an all-in commitment by every company with something to combat – COVID-19. Viren Mehta of Mehta Partners LLC discusses.

Mehta Analysis: Biopharma 3.0 – An Industry Society Could Cherish

As it enters a potentially golden decade, can biopharma seize the opportunity to overhaul its business model – and its reputation? Viren Mehta of Mehta Partners LLC discusses. 

Mehta Analysis: The New Decade Is Sure to Transform Biopharma Globally

Industry has the tools to bring more and far better treatments to more people faster than ever, with much lower R&D cost and very little selling needed for these targeted therapies – a perfect prescription for slashing prices for global access while preserving profits, argues Viren Mehta of Mehta Partners LLC.

Topics

UsernamePublicRestriction

Register

LL026487

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel